[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1162494A1 - 作為 抑制劑的碸取代的苯胺基嘧啶衍生物、其製備以及作為藥物的用途 - Google Patents

作為 抑制劑的碸取代的苯胺基嘧啶衍生物、其製備以及作為藥物的用途

Info

Publication number
HK1162494A1
HK1162494A1 HK12102924.3A HK12102924A HK1162494A1 HK 1162494 A1 HK1162494 A1 HK 1162494A1 HK 12102924 A HK12102924 A HK 12102924A HK 1162494 A1 HK1162494 A1 HK 1162494A1
Authority
HK
Hong Kong
Prior art keywords
cdk
sulfone
medicine
production
anilinopyrimidine derivatives
Prior art date
Application number
HK12102924.3A
Other languages
English (en)
Inventor
．吕金
．西邁斯特
．利瑙
．若泰拉特
．舒爾策
Original Assignee
拜耳知識產權有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳知識產權有限責任公司 filed Critical 拜耳知識產權有限責任公司
Publication of HK1162494A1 publication Critical patent/HK1162494A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12102924.3A 2008-10-21 2012-03-23 作為 抑制劑的碸取代的苯胺基嘧啶衍生物、其製備以及作為藥物的用途 HK1162494A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167115A EP2179992A1 (de) 2008-10-21 2008-10-21 Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007213 WO2010046034A1 (de) 2008-10-21 2009-10-08 Sulfonsubsituierte anilino-pyrimidinderivate als cdk-inhibitoren, deren herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HK1162494A1 true HK1162494A1 (zh) 2012-08-31

Family

ID=40282247

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102924.3A HK1162494A1 (zh) 2008-10-21 2012-03-23 作為 抑制劑的碸取代的苯胺基嘧啶衍生物、其製備以及作為藥物的用途

Country Status (9)

Country Link
US (1) US8802686B2 (zh)
EP (2) EP2179992A1 (zh)
JP (1) JP5667065B2 (zh)
KR (1) KR20110079902A (zh)
CN (1) CN102224144B (zh)
CA (1) CA2740616C (zh)
ES (1) ES2567709T3 (zh)
HK (1) HK1162494A1 (zh)
WO (1) WO2010046034A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US9656970B2 (en) 2014-05-08 2017-05-23 Tosoh F-Tech, Inc. 5-(trifluoromethyl)pyrimidine derivatives and method for producing same
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
AU2019340436A1 (en) 2018-09-10 2021-04-29 Mirati Therapeutics, Inc. Combination therapies
CA3202990A1 (en) * 2020-11-27 2022-06-02 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Aminoheteroaryl kinase inhibitors
WO2023226920A1 (en) * 2022-05-27 2023-11-30 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1999002162A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
EP1107958B1 (en) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
CA2449118A1 (en) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
DE50212771D1 (de) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003076437A1 (de) 2002-03-11 2003-09-18 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008528613A (ja) 2005-01-25 2008-07-31 ニューロジェン・コーポレーション 置換ピリダジニル−及びピリミジニル−キノリン−４−イルアミン類縁体
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102007010801A1 (de) * 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2010046034A1 (de) 2010-04-29
CN102224144B (zh) 2014-10-15
KR20110079902A (ko) 2011-07-11
JP5667065B2 (ja) 2015-02-12
US8802686B2 (en) 2014-08-12
EP2342185A1 (de) 2011-07-13
US20110251222A1 (en) 2011-10-13
CA2740616A1 (en) 2010-04-29
ES2567709T3 (es) 2016-04-26
EP2179992A1 (de) 2010-04-28
EP2342185B1 (de) 2016-01-13
CN102224144A (zh) 2011-10-19
JP2012506390A (ja) 2012-03-15
CA2740616C (en) 2016-08-23

Similar Documents

Publication Publication Date Title
ZA201103727B (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
HK1162494A1 (zh) 作為 抑制劑的碸取代的苯胺基嘧啶衍生物、其製備以及作為藥物的用途
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL219530A (en) Converted 4-aminocyclohexane compounds, drugs containing these compounds and their use in the preparation of drugs
ZA201000588B (en) Improved pharmaceutical-coated medical products,the production thereof and the use thereof
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
ZA200906751B (en) Enzyme for the production of methylmalonyl coenzyme A or ethylmalonyl coenzyme A, and use thereof
EP2157093A4 (en) HETEROCYCLIC PYRROLO-NITROGEN-DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
PT2242740E (pt) Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
ZA201008387B (en) Azacarboline derivatives,preparation thereof,and therapeutic use thereof as kinase inhibitors
EP2184277A4 (en) ARYLPYRIMIDINE DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL USES OF THE DERIVATIVES
ZA201107363B (en) Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof
ZA201200027B (en) Pyrazole derivatives, preparaton thereof, and therapeutic use thereof
EP2266619A4 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
IL212164A0 (en) The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof
PT2190913E (pt) Processo para a produção de formulações aquosas, formulações aquosas e a sua utilização
GB0711139D0 (en) New medicine use
EP2497768A4 (en) NEW 2,4-PYRIMIDINE DERIVATIVES AND USES THEREOF

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211008